BCL2 and breast carcinoma: Bcl-2 binding to SLIRP was validated by co-immunoprecipitation and co-localization experiments both in lung cancer and breast cancer cell models forced to overexpress bcl-2 and in HL60 and HeLa cell lines, expressing the endogenous bcl-2 protein.